Comparing two treatments for localized prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to compare the effectiveness and toxicity of Stereotactic Body RadioTherapy (SBRT) versus Low-Dose Rate Brachytherapy (LDRB) in patients with low and favorable intermediate-risk prostate cancer. The study will evaluate whether SBRT results in fewer genito-urinary and gastro-intestinal toxicities compared to LDRB, as well as assess the quality of life of patients receiving each treatment. By analyzing these factors, the trial seeks to provide valuable insights into the best treatment options for this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the prostate diagnosed within the last 8 months. Patients on active surveillance with evidence of disease progression are eligible to the protocol as long as they meet the eligibility criteria and have a recent prostate biopsy (within 8 months).
* Low-risk and favourable intermediate-risk prostate cancer patients are eligible according to the following definitions:

Low-risk disease defined as: Clinical stage T1-T2a and Gleason 6 and PSA ≤ 10 ng/mL

Favourable intermediate-risk cancer defined by a single NCCN intermediate risk factor:

\[NCCN : National Comprehensive Cancer Network\]

1. Clinical stage T2b
2. PSA \> 10 but ≤ 20 ng/mL
3. Gleason 7 (3+4)

Lymph node evaluation by either computed tomography (CT) or magnetic resonance imaging (MRI) is optional and is left at the discretion of the treating physician.

* Age ≥ 18 years
* Eastern Cooperative Oncology Group performance status 0-1
* Patient considered medically fit for LDR brachytherapy
* Prostate volume ≤ 60 cc, measured by Trans-Rectal UltraSound (TRUS), CT or MRI, within the last 6 months.
* International Prostate Symptom Score (IPSS) ≤ 20 (alpha blockers allowed)
* No alpha reductase inhibitors use within two weeks of randomization
* No hormonal therapy is accepted
* Patients must provide a study-specified informed consent form prior to study entry.
* Patients must be willing and able to complete the EPIC-26, IPSS and SHIM questionnaires.

\[EPIC-26: Expanded Prostate Cancer Index Composite score ; SHIM: Sexual Health Inventory for Men questionnaire\].

Exclusion Criteria:

* Clinical or radiological evidence of metastatic disease or nodal involvement.
* Clinical stage ≥ T2b.
* Gleason score ≥ 4 + 3.
* Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 3 years.
* Prior radical surgery for carcinoma of the prostate, or prior TURP (Trans-Urethral Resection of the Prostate).
* Prior pelvic radiotherapy or prior radiotherapy that would result in overlap of radiation fields.
* Prior chemotherapy for prostate cancer, or prior chemotherapy within the last 3 years.
* Prior cryosurgery of the prostate.
* Prior or current bleeding diathesis making fiducial placement or brachytherapy procedure unsafe.
* Previous androgen deprivation therapy within 6 months of the registration.
* Bilateral hip prostheses
* Any severe active comorbidity, laboratory abnormality, psychiatric illnesses, active or uncontrolled infections, serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision). Such examples includes active inflammatory bowel disease, significant urinary symptoms,

Where it's running

• Centre Intégré de Cancérologie, CHU de Québec-Université Laval
  Québec, Quebec, Canada Recruiting

Study contacts

• Study coordinator: Isabelle Thibault, MD, FRCPC
• Email: isabelle.thibault.med@ssss.gouv.qc.ca
• Phone: 418-525-4444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.